MA44560B2 - Anticorps anti-cd38 spécifiques pour le traitement de cancers humains - Google Patents

Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Info

Publication number
MA44560B2
MA44560B2 MA44560A MA44560A MA44560B2 MA 44560 B2 MA44560 B2 MA 44560B2 MA 44560 A MA44560 A MA 44560A MA 44560 A MA44560 A MA 44560A MA 44560 B2 MA44560 B2 MA 44560B2
Authority
MA
Morocco
Prior art keywords
antibody
medicament
treatment
antibodies specific
human cancers
Prior art date
Application number
MA44560A
Other languages
English (en)
Other versions
MA44560A1 (fr
MA44560B1 (fr
Inventor
Antoine Deslandes
Krzysztof Grzegorzewski
Marie-Laure Ozoux
Blake Tomkinson
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA44560A1 publication Critical patent/MA44560A1/fr
Publication of MA44560B1 publication Critical patent/MA44560B1/fr
Publication of MA44560B2 publication Critical patent/MA44560B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un anticorps qui se lie spécifiquement à cd38 qui est capable de tuer une cellule cd38+ par induction de l'apoptose, d'une cytotoxicité à médiation cellulaire dépendant des anticorps (adcc) et d'une cytotoxicité dépendant du complément. L'anticorps divulgué peut être utilisé comme médicament ou dans la préparation d'un médicament, l'anticorps étant à administrer à un sujet humain à une dose thérapeutique sûre d'environ 20 mg/kg ou inférieure. Dans un mode de réalisation, le médicament est destiné à traiter le myélome multiple à cd38+ chez des êtres humains.
MA44560A 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains MA44560B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306220 2014-07-31
PCT/US2014/063380 WO2015066450A1 (fr) 2013-10-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Publications (3)

Publication Number Publication Date
MA44560A1 MA44560A1 (fr) 2019-09-30
MA44560B1 MA44560B1 (fr) 2020-06-30
MA44560B2 true MA44560B2 (fr) 2021-01-29

Family

ID=51266255

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44560A MA44560B2 (fr) 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
MA39070A MA39070A1 (fr) 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA39070A MA39070A1 (fr) 2014-07-31 2014-10-31 Anticorps anti-cd38 spécifiques pour le traitement de cancers humains

Country Status (20)

Country Link
US (2) US20150118251A1 (fr)
EP (2) EP3805266A1 (fr)
JP (2) JP2016536314A (fr)
KR (1) KR20160077155A (fr)
CN (1) CN106103481A (fr)
AU (1) AU2014342103B2 (fr)
BR (1) BR112016009403A2 (fr)
CA (1) CA2927099A1 (fr)
CR (1) CR20160186A (fr)
EA (1) EA035098B1 (fr)
IL (1) IL245196B (fr)
MA (2) MA44560B2 (fr)
MX (1) MX2016005666A (fr)
NZ (1) NZ719784A (fr)
PL (1) PL3063173T3 (fr)
PT (1) PT3063173T (fr)
SG (2) SG10201803288RA (fr)
TN (1) TN2016000142A1 (fr)
TW (1) TW201522378A (fr)
WO (1) WO2015066450A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
PL2968555T3 (pl) * 2013-03-13 2020-11-16 Sanofi Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
EP3227338A4 (fr) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anticorps anti-cd38 pour le traitement de la leucémie aiguë myéloïde
US10533057B2 (en) * 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
AU2016264725B2 (en) 2015-05-20 2021-05-27 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
RS60441B1 (sr) 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
WO2016201337A1 (fr) * 2015-06-12 2016-12-15 Immungene, Inc. Molécules de fusion d'interféron et d'anticorps obtenues par génie génétique pour le traitement de cancers exprimant la protéine 94 régulée par le glucose (grp94)
JP6816038B2 (ja) 2015-06-22 2021-01-20 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MA53356B1 (fr) * 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
JP7362250B2 (ja) 2016-03-04 2023-10-17 モルフォシス・アーゲー 多発性骨髄腫におけるｍタンパク質反応の臨床評価
CA3029209A1 (fr) 2016-06-21 2017-12-28 Teneobio, Inc. Anticorps se liant a cd3
BR112019004873A2 (pt) 2016-09-14 2019-06-11 Teneobio Inc anticorpos de ligação a cd3
MX2019007379A (es) 2016-12-21 2019-09-18 Teneobio Inc Anticuerpos anti-bcma unicamente de cadena pesada.
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JPWO2019031444A1 (ja) * 2017-08-07 2020-08-27 国立大学法人九州大学 細胞集団における特異的結合物質の占有率を測定する方法
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
JP2020533362A (ja) * 2017-09-13 2020-11-19 テネオバイオ， インコーポレイテッド エクト酵素に結合する重鎖抗体
CA3079242A1 (fr) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methodes de traitement du myelome multiple a haut risque
KR20200076732A (ko) 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
BR112020019710A2 (pt) * 2018-03-28 2021-01-26 Takeda Pharmaceutical Company Limited métodos para tratar uma doença em um sujeito e para tratar um câncer hematológico em um sujeito, e, forma farmacêutica unitária.
SG11202104012QA (en) 2018-12-14 2021-05-28 Morphosys Ag Antibody formulations
EP3941489A4 (fr) * 2019-03-21 2022-12-28 Gamida-Cell Ltd. Fractions de cellules nk étendues appropriées pour une transplantation en polythérapie
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
WO2020252366A1 (fr) 2019-06-14 2020-12-17 Teneobio, Inc. Anticorps à chaînes lourdes multispécifiques se liant à cd22 et cd3
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
KR20220159947A (ko) 2019-12-05 2022-12-05 사노피-아벤티스 유.에스. 엘엘씨 피하 투여를 위한 항-cd38 항체의 제형
WO2021113754A1 (fr) * 2019-12-06 2021-06-10 Sanofi Utilisation d'isatuximab pour le traitement d'un myélome multiple réfractaire et/ou récidivant
JP2023532266A (ja) * 2020-06-23 2023-07-27 ジアンスー カニョン ファーマシューティカル カンパニー リミテッド 抗ｃｄ３８抗体及びその使用
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2024094660A1 (fr) * 2022-10-31 2024-05-10 Genmab A/S Anticorps cd38 et leurs utilisations

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
RU2224766C2 (ru) 1997-04-14 2004-02-27 Микромет Аг Способ получения рецепторов для человеческих антигенов и их применение
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2006125640A2 (fr) * 2005-05-24 2006-11-30 Morphosys Ag Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
CN1976950B (zh) * 2004-02-06 2012-08-29 莫佛塞斯公司 抗cd38人抗体及其用途
SI2567976T1 (sl) * 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
SI2081595T1 (sl) * 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
EP2191840A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
EP2191841A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
EP2191842A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
EP2191843A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3559049A4 (fr) * 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
PL2968555T3 (pl) * 2013-03-13 2020-11-16 Sanofi Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib

Also Published As

Publication number Publication date
AU2014342103A1 (en) 2016-05-26
JP2023109927A (ja) 2023-08-08
MA44560A1 (fr) 2019-09-30
CR20160186A (es) 2016-06-13
EA035098B1 (ru) 2020-04-27
CA2927099A1 (fr) 2015-05-07
KR20160077155A (ko) 2016-07-01
MA44560B1 (fr) 2020-06-30
AU2014342103B2 (en) 2020-06-04
JP2016536314A (ja) 2016-11-24
BR112016009403A2 (pt) 2017-09-19
US20150118251A1 (en) 2015-04-30
WO2015066450A1 (fr) 2015-05-07
US20180022814A1 (en) 2018-01-25
TW201522378A (zh) 2015-06-16
MA39070A1 (fr) 2017-11-30
TN2016000142A1 (en) 2017-10-06
PT3063173T (pt) 2020-10-20
EP3063173A1 (fr) 2016-09-07
EP3805266A1 (fr) 2021-04-14
PL3063173T3 (pl) 2021-01-11
CN106103481A (zh) 2016-11-09
SG10201803288RA (en) 2018-05-30
NZ719784A (en) 2022-02-25
IL245196A0 (en) 2016-06-30
IL245196B (en) 2021-04-29
SG11201603088RA (en) 2016-05-30
EA201690905A1 (ru) 2016-08-31
EP3063173B1 (fr) 2020-07-29
MX2016005666A (es) 2016-07-14

Similar Documents

Publication Publication Date Title
MA44560B2 (fr) Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
JP2016536314A5 (fr)
JP2017507954A5 (fr)
JP2018516969A5 (fr)
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
MY191423A (en) Binding molecules specific for cd73 and uses thereof
MX2014001374A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2015007343A (es) Dosis de inmunoconjugados de anticuerpos y sn-38 para eficacia mejorada y toxicidad reducida.
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201892541A1 (ru) Гуманизированные анти-il-1r3 антитела
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
CA2939464A1 (fr) Utilisation d'anticorps anti-ccr5 dans la maladie du greffon contre l'hote
EA201370162A1 (ru) Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
JP2017537927A5 (fr)
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
EP3991749A3 (fr) Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps
JP2019533682A5 (fr)
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.